Biotech, pharma outsourcing market to hit $128.9Bn by 2034: Market.us

NEW YORK, UNITED STATES — The global biotechnology and pharmaceutical services outsourcing market is projected to reach $128.9 billion by 2034, growing at a 6.1% CAGR, according to a Market.us report, as companies seek efficiency, reduced costs, and faster drug development.

Biotechnology and pharmaceutical services outsourcing is a business approach in which firms outsource the provision of key business functions to external sources, such as the discovery and clinical development of drugs, the production and commercialization of drug and pharmaceutical products.

This enables companies to tap available expertise across the globe, enhance their operational flexibility, and accelerate the introduction of new therapies in the international market.

Market expansion fueled by efficiency, specialization

The sector has a compound annual growth rate (CAGR) of 6.1%, an expansion that underscores a strategic shift toward specialized external partnerships.

This has been mainly due to the biopharmaceutical companies that struggle to automate their operations, cope with difficult regulatory environments, and shorten drug development cycles through outsourcing.

This strategic change enables companies to specialize in areas of core competencies, such as research, and outsource special functions. 

This area includes consulting services that hold the biggest market share of 26.5% because companies look for external partners to avoid extra costs and risks when creating strategies, marketing, and clinics.

Large enterprises dominate as SMEs eye fast growth

Large enterprises now have a market share of 74.6% and dominate the market. Their extensive financial resources and global infrastructure are at their disposal, enabling them to outsource on a large scale, gain economies of scale, accelerate the development of drugs, and be within the frameworks and regulations of existing international systems and regulatory bodies.

Small and medium enterprises (SMEs), on the other hand, are characterized by a low percentage but can exhibit extremely high growth rates. 

Limited resources on the part of the company and a constrained budget have seen outsourcing being a major strategy that SMEs have employed to stay afloat, minimize operational risks, and concentrate on innovations without necessarily having to invest so much money in activities like clinical trials and regulatory support.

Key players driving biotech and pharma outsourcing sector

The competitive field includes a diverse mix of global giants and specialized firms offering a wide array of services from clinical research to manufacturing. 

• Parexel International Corporation
• LabCorp
• IQVIA
• Lonza
• Concept Heidelberg GmbH
• Samsung Biologics
• Charles River Laboratories
• ICON plc.
• Syneos Health
• Lachman Consultant Services, Inc.
• Catalent Inc.
• GMP Pharmaceuticals Pty Ltd.
• The Quantic Group

This ecosystem is characterized by strategic mergers, acquisitions, and technology adoption, as seen in Lonza’s acquisition of a Genentech manufacturing facility, valued at $1.2 billion, and Parexel’s acquisition of ExecuPharm to enhance and strengthen its capacity in clinical studies.

North America retains 40% share amid global shifts

North America took the lead in the region in 2024, with a 40.3% share valued at $28.7 billion. This is due to the advanced level of healthcare, accessibility of pharmaceutical companies, high scale of clinical trials, and a cordial regulatory environment, which the United States Food and Drug Administration (FDA) enabled.

Geopolitical tensions and supply chain reevaluation are two factors worldwide that are changing the market. Other moves, such as the U.S. Biosecure Act, are deterring collaboration with some Chinese companies and forcing businesses to diversify the supplier base. 

Simultaneously, India is emerging as a giant hub, with over 2.86 billion government subsidies to enable its biotechnology sector and to create contract research, development, and manufacturing organization (CRDMO) parks.

This projected expansion will redefine global supply chains, with outsourcing serving as the essential backbone of biotechnology and pharmaceutical innovation over the coming years.